Name: Latest research reports of Ajanta Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 1
Author: BOB Capital Markets Ltd.

Ajanta Pharma (SELL): No incremental triggers; valuation expensive

Sell: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

At our virtual conference AJP said it is not looking to venture into newer therapies in India in the next 1-2 years due to hefty valuations